Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">The Medicines Co (MDCO), Sanofi (SNY), Amgen (AMGN) high following positive Repatha data from Amgen last night: Analyst color (38.00)<ul><li>Chardan notes Amgen (unrated) announced the ~27,500 patient FOURIER cardiovascular outcomes study (CVOT) testinganti-PCSK9 monoclonal antibody inhibitor, Repatha, met its primary and key secondary endpoint. Given the positive topline results and the likely permanent injunction of Neutral-rated Regeneron's (<strong>REGN</strong>, <strong>SNY</strong>) PCSK9 inhibitor, Praluent, they reiterate their long-held belief that Amgen (with marketed Repatha) and partners, the Medicines Company (MDCO, Buy) and Alnylam (ALNY, Buy) (with phase III inclisiran), are the best ways to invest in the theme of the emergence of PCSK9 inhibitors. With the news overnight they reiterate their view of MDCO as a Chardan top pick for 2017.</li><li>H.C. Wainwright notes MDCO spiked up at least $5.60 (14.7%) on the long-awaited release of top-line data from FOURIER, Amgen's (AMGN; not rated) large cardiovascular outcomes trial (CVOT) of its marketed PCSK9 inhibitor, Repatha (evolocumab), with clear positive read-throughs to MDCO's lead pipeline asset, inclisiran (PCSK9si), given the same mechanism of action (MOA) leads to a putative (and quite likely) class effect. Detailed results from FOURIER are under strict embargo until they are presented at the American College of Cardiology (ACC) 66th Annual Scientific Session Late-Breaking Clinical Trials session in Washington, D.C. on Friday, March 17 believe the combination of full data from ORION-1 and FOURIER represents a truly substantial catalyst event for MDCO shares, and <strong>recommend investors consider either establishing or adding to their MDCO positions ahead of the conference embargo release in March.</strong></li><li><strong>MDCO</strong> +9%, <strong>AMGN</strong> +2.6%, <strong>ALNY</strong> +0.3%… competitors <strong>REGN</strong> +1%, <strong>SNY</strong> +0.1%</li></ul></td> </tr></table>"